CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.
about
Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?Serum sdLDL-C and Cellular SREBP2-dependent Cholesterol Levels; is there a Challenge on Targeting PCSK9?Baccaurea angulata fruit juice reduces atherosclerotic lesions in diet-induced Hypercholesterolemic rabbitsInhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathwayAnacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levelsAnacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.Modulation of cholesterol transport by maternal hypercholesterolemia in human full-term placentaPolydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention.Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?Cholesteryl ester transfer protein inhibitors: challenges and perspectives.New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.Identification of Hepatic Lysophosphatidylcholine Acyltransferase 3 as a Novel Target Gene Regulated by Peroxisome Proliferator-activated Receptor δ.Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression in vitro and in vivo.Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters.New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.Sauchinone controls hepatic cholesterol homeostasis by the negative regulation of PCSK9 transcriptional network.Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism.
P2860
Q28080768-70AD27F4-4C9A-4138-B3CF-067164BEF7C3Q33801003-379359E3-CA5E-41FD-98CA-826D95242DC0Q33882916-BBDFF0FA-0FE0-4D18-9C43-6FAB98CE10CBQ34455663-E6A33AF0-A5F6-45DB-836E-379BFED36349Q35836143-A3CAB420-9272-48AC-8D7B-B2D11C08095AQ35911079-6C856202-652D-420F-A926-8264E5EB7B47Q36197815-C66F8C59-9286-4A1A-A785-6A3FAA0E8013Q36281404-66F1EDC1-40FC-439F-8EE2-CA9DC136626CQ36529674-CD45C6F6-36A3-466D-9D57-C4DFBE156AA8Q37150845-E56E8E2B-FE78-4390-99C1-EA7F4059287FQ38415231-76CE057E-4AD5-4AB8-B256-447E8229CA0FQ38424373-424FCCAB-52CE-439A-9D3E-F93DBD8D7F0BQ38661093-807CDF5C-B546-4F18-91DA-F4BEC68F3383Q38832774-0B22ACBA-555E-4089-940B-2CEEA5A3C776Q38870490-859A050E-5BBA-4867-979D-2DF0FA65A13EQ44417767-0899747B-6F02-4E43-8603-D3D2B41F643EQ47132548-8ED12CD0-E055-4FA7-A813-FCF3BAA599BCQ48016243-B837CA13-6804-45E5-82F1-F58C846CF903Q50044216-1F8D84DF-D27C-4650-B041-A952CC42285AQ52715410-3541DB21-2B32-48DC-8DFD-F1A0CBFA2053Q52721601-60200CCC-5160-435A-95C5-75DC0DADEFF6
P2860
CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
CETP inhibitors downregulate h ...... a SREBP2 dependent mechanism.
@ast
CETP inhibitors downregulate h ...... a SREBP2 dependent mechanism.
@en
type
label
CETP inhibitors downregulate h ...... a SREBP2 dependent mechanism.
@ast
CETP inhibitors downregulate h ...... a SREBP2 dependent mechanism.
@en
prefLabel
CETP inhibitors downregulate h ...... a SREBP2 dependent mechanism.
@ast
CETP inhibitors downregulate h ...... a SREBP2 dependent mechanism.
@en
P2093
P2860
P1433
P1476
CETP inhibitors downregulate h ...... h a SREBP2 dependent mechanism
@en
P2093
P2860
P304
P356
10.1016/J.ATHEROSCLEROSIS.2014.05.931
P577
2014-06-04T00:00:00Z